With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved ...

He set me up with a treatment plan, which was reassuring. I was started immediately on Atripla, a drug used to inhibit HIV.

The fixed-dose combination was first approved as Atripla in the United States in 2006 and in the European Union in late 2007. Numerous generic versions are also available. Branded Atripla will be ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

The new product gives ViiV a weapon against the dominance of Gilead in the first-line HIV therapy market, which is led by the company's Atripla (efavirenz, emtricitabine, and tenofovir ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

The trial will seek relief for anyone who was prescribed TDF drugs in Canada under the brands Viread, Truvada, Atripla, Complera or Stribild. The plaintiffs seek relief for general, special and ...

Modera Wealth Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.9% in ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...